Accounting for almost 20% of cancers worldwide, urologic cancers include malignancies of the prostate, bladder, kidney and testes. The Department of Urology is home to an outstanding team of scientists, clinicians and fellowship-trained urologic oncologists with significant expertise in urologic cancers. Together, our physicians and basic science researchers are working to increase our understanding of the biology of urologic cancers, create innovative tools to distinguish aggressive disease, develop novel and more effective treatments, and to improve the overall survival and wellbeing of patients.
Conditions we treat within this category include:
- Bladder cancer
- Kidney cancer
- Testis cancer
- Prostate cancer
The Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital offers comprehensive care for patients with all forms of urologic cancer. Our new multidisciplinary institute sets a new standard in urologic cancer care. Learn more about the types of cancers we treat, their symptoms, and our approach to diagnosis and treatment at https://www.feinberg.northwestern.edu/sites/urologic-oncology/.
Clinical Investigator, Joshua Meeks, MD, PhD, is researching the underlying genetics of bladder cancer to develop new treatments for the disease while Shilajit Kundu, MD, is conducting research on cancer outcomes and quality-of-life issues. The Department of Urology is also participating in several clinical trials to test the efficacy of new therapies and technologies for bladder cancer and to identify effective ways to improve quality of life.
Meeks JJ, Lerner S. Molecular Landscape of Non-Muscle Invasive Bladder Cancer. Cancer Cell, November 2017.
Matulewicz RS, Meeks JJ. Testicular Mass. JAMA, August 2016.
Meeks JJ, Gonzalez CM. Standard of Care for Small Renal Masses in the 21st Century. JAMA Surgery, July 2015.
The Department of Urology offers access to the most advanced approaches in genitourinary cancer prevention, diagnosis and treatment from experts who understand the challenges and concerns unique to patients faced with urologic cancers. We pursue a multidisciplinary approach to the evaluation and management with recognized experts specializing in each branch of cancer care. The integrated approach with input from all related services allows for the formulation of an appropriate treatment plan individualized for each patient based upon tumor stage, medical condition, and patient preferences.
Shilajit Kundu, MD
Chief of Urologic Oncology in the Department of Urology
Associate Professor of Urology